Department of Internal Medicine, University of Illinois Chicago, Chicago, IL, USA.
Division of Gastroenterology and Hepatology, University of Illinois Chicago, Chicago, IL, USA.
Int J Colorectal Dis. 2021 Jun;36(6):1193-1200. doi: 10.1007/s00384-021-03852-7. Epub 2021 Jan 23.
Opioid analgesic use is associated with increased mortality, higher readmission rates, and reduced quality of life among patients with inflammatory bowel disease (IBD). With the goal of reducing inpatient opioid use among patients with IBD admitted to our inpatient gastroenterology (GI) service, we designed and implemented a standardized, educational intervention providing analgesic decision support to internal medicine and emergency medicine housestaff at our institution.
Pre-intervention data was collected from patients admitted during a 9-month period prior to intervention. Post-intervention patients were identified prospectively. The primary outcome was reduction in aggregate inpatient opioid use in oral morphine equivalents per patient.
A total of 68 patients with 81 hospitalizations were analyzed. There was no statistically significant difference in baseline admission characteristics between the two groups. Our primary outcome was achieved with a statistically significant reduction in opioid use during hospitalization (43.4 mg vs 7.7 mg; p < 0.01). Secondary outcomes achieved included reduction in new opioid prescriptions upon discharge, reduced hospital length of stay, and reduced 90-day readmission rates. There was no significant difference between patients' pain scores between the two groups.
We believe this intervention, aimed at housestaff education, provides a roadmap for pain management decision-making in this patient population. It is a readily reproducible strategy that can be widely applied to improve inpatient IBD patient care. Importantly, patient experience and pain scores were unchanged despite lower use of inpatient opioid analgesia, highlighting successful opioid-sparing analgesics in most inpatients with IBD.
阿片类镇痛药的使用与炎症性肠病(IBD)患者的死亡率增加、再入院率升高和生活质量降低有关。为了减少我院住院胃肠病学(GI)服务收治的 IBD 患者的住院阿片类药物使用量,我们设计并实施了一项标准化的教育干预措施,为我们机构的内科和急诊住院医师提供镇痛决策支持。
在干预前的 9 个月期间收集了接受干预前患者的数据。前瞻性地识别了接受干预后的患者。主要结局是减少每位患者的住院口服吗啡等效物的总体阿片类药物使用量。
共分析了 68 例患者的 81 例住院情况。两组患者的基线入院特征无统计学差异。我们的主要结局是在住院期间的阿片类药物使用量显著减少(43.4mg 比 7.7mg;p<0.01)。达到的次要结局包括出院时新的阿片类药物处方减少、住院时间缩短和 90 天再入院率降低。两组患者的疼痛评分无显著差异。
我们认为,针对住院医师教育的这种干预措施为该患者人群的疼痛管理决策提供了指导。这是一种易于复制的策略,可以广泛应用于改善 IBD 住院患者的护理。重要的是,尽管住院阿片类镇痛药使用量减少,但患者的体验和疼痛评分没有改变,这突出了大多数 IBD 住院患者成功使用了阿片类药物节约型镇痛剂。